Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL1 | P55085 | 6/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | DPP4 | P27487 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.41 |
| ▸ | TRPC7 | Q9HCX4 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CCKAR | P32238 | 2/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16614517 | 0.89 | F2RL1 (0.64) | F2RL1LMNADPP4TSHRKDM4E | |
| SCHEMBL16614557 | 0.89 | F2RL1 (0.48) | F2RL1LMNADPP4TSHRKDM4E | |
| SCHEMBL16599357 | 0.83 | NPC1 (0.49) | F2RL1DPP4KDM4ETP53HSD17B10 | |
| SCHEMBL16614547 | 0.83 | F2RL1 (0.46) | F2RL1LMNADPP4TSHRKDM4E | |
| SCHEMBL18179257 | 0.80 | F2RL1 (0.47) | F2RL1DPP4TSHRKDM4ETP53 | |
| SCHEMBL16614839 | 0.79 | F2RL1 (0.49) | F2RL1LMNADPP4TSHRKDM4E | |
| SCHEMBL16598854 | 0.78 | F2RL1 (0.50) | F2RL1 | |
| SCHEMBL16598329 | 0.77 | F2RL1 (0.61) | F2RL1KDM4EHSD17B10HTTHPGD | |
| SCHEMBL16598490 | 0.77 | KDM4E (0.44) | F2RL1KDM4ETP53HSD17B10HPGD | |
| SCHEMBL16614543 | 0.76 | F2RL1 (0.67) | F2RL1LMNATSHRKDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190119282-A1 | IMIDAZOPYRIDAZINES USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS INCORPORATED | 2019-04-25 | — | — | US | disclosed |
| US-10030024-B2 | Imidazopyridazines useful as inhibitors of the PAR-2 signaling pathway | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-07-24 | — | — | US | disclosed |
| US-10030024-B2 | Imidazopyridazines useful as inhibitors of the PAR-2 signaling pathway | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-07-24 | — | — | US | disclosed |
| US-20160311825-A1 | IMIDAZOPYRIDAZINES USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2016-10-27 | — | — | US | disclosed |
| US-20160311825-A1 | IMIDAZOPYRIDAZINES USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2016-10-27 | — | — | US | disclosed |
| WO-2015048245-A1 | IMIDAZOPYRIDAZINES USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119282-A1 | IMIDAZOPYRIDAZINES USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | F2RL1, F2R, F2RL3 | F2RL1 1/4885LMNA 1735/4885DPP4 195/4885 |
| US-20160311825-A1 | IMIDAZOPYRIDAZINES USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | F2RL1, F2R, F2RL3 | F2RL1 1/4885LMNA 1735/4885DPP4 195/4885 |
| US-10030024-B2 | Imidazopyridazines useful as inhibitors of the PAR-2 signaling pathway | F2RL1, F2R, F2RL3 | F2RL1 1/4885LMNA 1735/4885DPP4 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.